Compare Danaos Corporation (DAC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaos Corporation vs Novo Nordisk A/S — how do they compare? Danaos Corporation trades at $169.09 (market cap $3.10B), while Novo Nordisk A/S trades at $38.6 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 53.3× Danaos Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Danaos Corporation for 25 Days and Novo Nordisk A/S for 116 Days on average.
| DAC | NVO | |
|---|---|---|
Market Cap | $3.10B | $165.31B |
Volume | 286,008 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $170.22 | $63.98 |
52-Week Low | $84.05 | $35.29 |
Typical Hold Time | 25 Days | 116 Days |
Enterprise Value | $3.08B | $179.56B |
Dividend Yield | 2.35% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DAC trades at $169.09, up 2.8% today, with a bullish technical signal and strong fundamental metrics. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $7.29 exceeding the $6.80 estimate. Valuation ratios are attractive, including a P/E of 5.76 and P/B of 0.76, while profitability remains high with a net income margin of 51.26%. Recent news highlights dividend declarations and institutional investment interest.
The outlook is positive given earnings momentum and shareholder returns via dividends, but risks include shipping market volatility and reliance on global trade flows. Analyst consensus is evenly split between Buy and Hold ratings, suggesting cautious optimism amid strong operational performance.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
